

*Sub
B2*

In the Claims:

Please add claims 92-95 as follows:

*Sub
B2*

92. The method of claim 86 wherein the compound is administered daily for 3 days with a period of 4 days between cycles where there is no treatment.

93. The method of claim 87 wherein the compound is administered daily for 3 days with a period of 4 days between cycles where there is no treatment.

*Sub
B2*

94. The method of claim 86 wherein the compound is administered daily for 5 days with a period of 2 days between cycles where there is no treatment.

95. The method of claim 87 wherein the compound is administered daily for 5 days with a period of 2 days between cycles where there is no treatment.

REMARKS

The "Cross-Reference to Related Applications" section of the specification has been amended to correct an error in the application number of the provisional application filed on May 11, 2001. Attached is Appendix A showing the changes made with additions shown as underlined text and deleted text included in brackets.

Furthermore, claims 92-95 have been added. The subject matter included in these claims is described in the specification on page 19, lines 17-23 (for claims 92 and 93) and page 19, lines 29-31 (for claims 94 and 95). Accordingly, no new matter has been added.

In view of the above amendments, Applicants respectfully submit that the application is in proper condition for examination. An early action on the merits, therefore, is earnestly solicited.

Respectfully submitted,



Rena Patel, Ph.D.
for Applicants
Reg. No. 41,412

Date: **May 13, 2002**

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5398